CYC116

• CAS: 693228-63-6
• Catalog Number: ACM693228636
• Category: Inhibitors
• Molecular Weight: 368.46
• Molecular Formula: C18H20N6OS
• Description: CYC116 is an orally bioavailable small molecule multi-kinase inhibitor with antineoplastic activity. Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis. Aurora kinases are serine/threonine protein kinases that are only expressed in actively dividing cells and are critical in division or mitosis. VEGFR2 is a receptor tyrosine kinase that appears to account for most of the mitogenic and chemotactic effects of vascular endothelial growth factor (VEGF) on adult endothelial cells.
• Synonyms: CYC116; CYC 116; CYC-116
• IUPAC Name: 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine
• Canonical SMILES: NC1=NC(C)=C(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)S1
• InChI: InChI=1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)
• InChI Key: GPSZYOIFQZPWEJ-UHFFFAOYSA-N
• Solubility: Soluble in DMSO, not in water
• Appearance: Solid powder
• Shelf Life: >5 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Biological Target: CYC-116 is a potent aurora A and aurora B inhibitor with Kis of 8 and 9 nM, respectively.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 58.68; H, 5.47; N, 22.81; O, 4.34; S, 8.70
• Exact Mass: 368.14193
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: The degranulation in BMMCs caused by antigen was inhibited by CYC116 in a dose-dependent manner (IC50, ~1.42 µM) (Fig. 2A).; Reference: Biomol Ther (Seoul). 2019 May 1;27(3):311-317. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513188/
• In Vivo Activity: Through cell-based screening of kinase-directed compound collection, this study discovered that a subset of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amines (including CYC116) were potent cytotoxic agents against cancer cell lines, suppressed mitotic histone H3 phosphorylation, and caused aberrant mitotic phenotypes. It was subsequently established that these compounds were in fact potent inhibitors of aurora A and B kinases. The anticancer effects of lead compound 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine (18; K(i) values of 8.0 and 9.2 nM for aurora A and B, respectively) were shown to emanate from cell death following mitotic failure and increased polyploidy as a consequence of cellular inhibition of aurora A and B kinases.; Reference: J Med Chem. 2010 Jun 10;53(11):4367-78. https://pubmed.ncbi.nlm.nih.gov/20462263/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).